Abstract

The design, synthesis and formulation of non‐viral gene delivery vectors is an area of renewed research interest. Amongst the most efficient non‐viral gene delivery systems are lipopolyplexes, in which cationic peptides are co‐formulated with plasmid DNA and lipids. One advantage of lipopolyplex vectors is that they have the potential to be targeted to specific cell types by attaching peptide targeting ligands on the surface, thus increasing both the transfection efficiency and selectivity for disease targets such as cancer cells. In this paper, we have investigated two different modes of displaying cell‐specific peptide targeting ligands at the surface of lipopolyplexes. Lipopolyplexes formulated with bimodal peptides, with both receptor binding and DNA condensing sequences, were compared with lipopolyplexes with the peptide targeting ligand directly conjugated to one of the lipids. Three EGFR targeting peptide sequences were studied, together with a range of lipid formulations and maleimide lipid structures. The biophysical properties of the lipopolyplexes and their transfection efficiencies in a basal‐like breast cancer cell line were investigated using plasmid DNA bearing genes for the expression of firefly luciferase and green fluorescent protein. Fluorescence quenching experiments were also used to probe the macromolecular organisation of the peptide and pDNA components of the lipopolyplexes. We demonstrated that both approaches to lipopolyplex targeting give reasonable transfection efficiencies, and the transfection efficiency of each lipopolyplex formulation is highly dependent on the sequence of the targeting peptide. To achieve maximum therapeutic efficiency, different peptide targeting sequences and lipopolyplex architectures should be investigated for each target cell type.

Highlights

  • The delivery of oligonucleotide or genetic material to specific cells has been a long‐term goal for treatment of intractable diseases such as cancer, cystic fibrosis, retinal disorders, and cardiovascular disease

  • We have previously shown that this necessitates the targeting peptide protruding through the surface of the lipid layer, resulting in the “bifunctional peptide” design shown in Figure 1.24 For these lipopolyplex formulations, peptides P1, P2, and P3 were synthesised, with K16 condensing sequences, the RVRR enzymatically cleavable linker, and the GE11 (P1), D4 (P2), or AE (P3) sequences

  • When DODSM 1 was used as the maleimide bearing component (lipopolyplexes F1‐(P4,P7), F1‐(P5,P7), and F1‐(P6, P7)) the bioluminescence output was similar to the control non‐targeted lipopolyplex F7‐(P7)‐REF at 24 hours but exhibited a SCHEME 2 Schematic showing the preparation of surface targeted lipopolyplexes distinctive increase (1.5‐1.8 fold) at 48 hours

Read more

Summary

| INTRODUCTION

The delivery of oligonucleotide or genetic material to specific cells has been a long‐term goal for treatment of intractable diseases such as cancer, cystic fibrosis, retinal disorders, and cardiovascular disease. For example: formulation of LPD nanoparticles using cationic lipids and peptide sequences derived from protamine or histone resulted in enhancement of cell transfection in vitro[16]; in early work, RGD‐ targeted LPD revealed a 30‐fold increase in cell transfection compared with the use of naked DNA17; lipopolyplexes incorporating a fusion protein consisting of the carboxy‐terminal domain of histone H1 and a nuclear localization signal gave transfection efficiencies up to 20‐fold higher than lipofectin/DNA complexes.[18] We have previously developed targeted, environmentally responsive lipid:peptide:DNA (LPD) lipopolyplexes for gene delivery These lipopolyplex formulations contain a bimodal peptide with a cationic sequence to bind and condense pDNA,[19] a linker sequence (RVRR) which can be cleaved by enzymes within the endosome, and a targeting sequence.[20] The formulation of the lipopolyplexes includes cationic lipids such as DOTMA, and the helper lipid 1,2‐dioleoyl‐sn‐ glycero‐3‐phosphoethanolamine (DOPE). We have used pDNA that has optical readouts through the expression of either firefly luciferase[33,34] or green fluorescent protein (GFP)[35] with the aim that the lipopolyplex formulations could be applied to other targeted gene‐based therapy approaches

| MATERIALS AND METHODS
| RESULTS AND DISCUSSION
| CONCLUSIONS
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call